nach oben

Erschienen in:

18.07.2017 | Original Article

FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma

verfasst von: Joshua I. Warrick, Matthew Kaag, Jay D. Raman, Wilson Chan, Truc Tran, Sudhir Kunchala, Lauren Shuman, David DeGraff, Guoli Chen

Erschienen in: Virchows Archiv | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Invasive bladder cancer is diverse, and includes several named histomorphologies that differ from conventional urothelial carcinoma, termed “histologic variants.” By transcriptional analysis, bladder cancers can be divided into luminal and basal subtypes. In this paper, we study associations between markers of transcriptional subtypes and variant histology in a retrospective cohort of 309 cystectomy specimens. Histology slides were methodically reviewed for all cases, and variant histology was documented. Immunohistochemistry for FOXA1 (luminal marker) and CK14 (basal maker) was performed on histologic variants and their associated conventional urothelial carcinomas. Invasive carcinoma was present in 270 of the cystectomy specimens, 35% of which contained a histologic variant. Squamous carcinomas expressed higher CK14 levels than micropapillary, nested, and plasmacytoid carcinomas (p < 0.001, Kruskal-Wallis), keeping with the basal character of squamous carcinoma. Likewise, squamous carcinomas expressed lower FOXA1 levels than micropapillary, nested, and plasmacytoid carcinomas (p < 0.001, Kruskal-Wallis), keeping with the luminal character of micropapillary carcinoma, and suggesting that nested and plasmacytoid cancers have luminal character. FOXA1 was expressed at lower levels in conventional urothelial carcinoma associated with squamous carcinoma than conventional urothelial carcinoma associated with micropapillary carcinoma (p = 0.0072, Wilcoxon rank sum). CK14 expression did not differ between conventional urothelial carcinomas associated with squamous versus micropapillary carcinoma (p = 0.89, Wilcoxon rank sum). Instead, CK14 expression was higher in squamous carcinoma than conventional urothelial carcinoma present in the same bladder (p = 0.014, Wilcoxon rank sum, paired). Overall, the findings show that squamous and micropapillary cancers have different expression patterns of CK14 and FOXA1 and suggest that they arise from distinct precursors.

Nur mit Berechtigung zugänglich

Amin MB (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 22 Suppl 2:S96–S118. doi:10.1038/modpathol.2009.26 CrossRefPubMed

Grignon DJ, Al-Ahmadie H, Algaba F, Amin MB, Comperat E, Dryskjot L, Epstein JI, Hansel DE, Knuchel R, Lloreta J, Lopez-Beltran A, McKenney JK, Netto GJ, Paner G, Reuter VE, Shen SS, Van der Kwast T (2016) Infiltrating Urothelial Carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds) WHO classificaiton of tumours of the urinary system and male genital organs, 4th edn. International Agencyfor Research on Cancer (IARC), Lyon

Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL (2007) Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62–67. doi:10.1002/cncr.22756 CrossRefPubMed

Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881–885. doi:10.1016/S0022-5347(05)00423-4 CrossRefPubMed

Sui W, Matulay JT, James MB, Onyeji IC, Theofanides MC, RoyChoudhury A, DeCastro GJ, Wenske S (2016) Micropapillary bladder cancer: insights from the National Cancer Database. Bladder Cancer 2(4):415–423. doi:10.3233/blc-160066 CrossRefPubMedPubMedCentral

Spaliviero M, Dalbagni G, Bochner BH, Poon BY, Huang H, Al-Ahmadie HA, Donahue TF, Taylor JM, Meeks JJ, Sjoberg DD, Donat SM, Reuter VE, Herr HW (2014) Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. J Urol 192(3):702–707. doi:10.1016/j.juro.2014.02.2565 CrossRefPubMedPubMedCentral

Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Faba O, Villavicencio H (2010) The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 17(5):5370–5376PubMed

Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322. doi:10.1038/nature12965 CrossRef

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152–165. doi:10.1016/j.ccr.2014.01.009 CrossRefPubMedPubMedCentral

10.

Chou R, Selph SS, Buckley DI, Gustafson KS, Griffin JC, Grusing SE, Gore JL (2016) Treatment of muscle-invasive bladder cancer: a systematic review. Cancer 122(6):842–851. doi:10.1002/cncr.29843 CrossRefPubMed

11.

Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111(8):3110–3115. doi:10.1073/pnas.1318376111 CrossRefPubMedPubMedCentral

12.

Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Ferno M, Ringner M, Mansson W, Liedberg F, Lindgren D, Hoglund M (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18(12):3377–3386. doi:10.1158/1078-0432.CCR-12-0077-T CrossRefPubMed

13.

Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ (2014) Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400–410. doi:10.1038/nrurol.2014.129 CrossRefPubMed

14.

Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B (2016) Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur Urol 70(4):611–620. doi:10.1016/j.eururo.2016.02.056 CrossRefPubMed

15.

Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, Ro JY, Shah RB, Shen SS, Tamboli P, McKenney JK (2010) Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 34(9):1367–1376. doi:10.1097/PAS.0b013e3181ec86b3 CrossRefPubMed

16.

Shah TS, Kaag M, Raman JD, Chan W, Tran T, Kunchala S, Shuman L, DeGraff DJ, Chen G, Warrick JI (2016) Clinical significance of prominent retraction clefts in invasive urothelial carcinoma. Hum Pathol. doi:10.1016/j.humpath.2016.10.021

17.

Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Neuzillet Y, Denoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6(244):244ra291. doi:10.1126/scitranslmed.3008970 CrossRef

18.

Warrick JI, Walter V, Yamashita H, Chung E, Shuman L, Amponsa VO, Zheng Z, Chan W, Whitcomb TL, Yue F, Iyyanki T, Kawasawa YI, Kaag M, Guo W, Raman JD, Park JS, DeGraff DJ (2016) FOXA1, GATA3 and PPAR cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci Rep 6:38531. doi:10.1038/srep38531 CrossRefPubMedPubMedCentral

19.

Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA 3rd, Smith JA Jr, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ (2015) Loss of FOXA1 drives sexually dimorphic changes in urothelial differentiation and is an independent predictor of poor prognosis in bladder cancer. Am J Pathol 185(5):1385–1395. doi:10.1016/j.ajpath.2015.01.014 CrossRefPubMedPubMedCentral

20.

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ (2012) Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One 7(5):e36669. doi:10.1371/journal.pone.0036669 CrossRefPubMedPubMedCentral

21.

Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ (2016) Altered expression of the transcription factor forkhead box A1 (FOXA1) is associated with poor prognosis in urothelial carcinoma of the upper urinary tract. Urology 94(314):e311–e317. doi:10.1016/j.urology.2016.05.030

22.

Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, DeGraff DJ (2017) On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nat Rev Urol 14(2):98–106. doi:10.1038/nrurol.2016.239 CrossRefPubMed

23.

Ho PL, Kurtova A, Chan KS (2012) Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 9(10):583–594. doi:10.1038/nrurol.2012.142 CrossRefPubMedPubMedCentral

24.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481. doi:10.1200/JCO.1999.17.5.1474 CrossRefPubMed

25.

Team RC (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

26.

Giraudoux P (2016) Pgirmess: data analysis in ecology. R package version 1.6.5. https://CRAN.R-project.org/package=pgirmess. Accessed 1 June 2016

27.

Wickham H (2009) Ggplot2: elegant graphics for data analysis. Use R! Springer, New YorkCrossRef

28.

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf 12:77. doi:10.1186/1471-2105-12-77 CrossRef

29.

Warrick JI, Kaag M, Raman JD, Chan W, Tran T, Kunchala S, DeGraff D, Chen G (2016) Squamous dysplasia of the urinary bladder: a consecutive cystectomy series. Int J Surg Pathol 24(4):306–314. doi:10.1177/1066896916629783 CrossRefPubMed

30.

Harnden P, Southgate J (1997) Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol 50(12):1032–1033CrossRefPubMedPubMedCentral

31.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research N, Benz CC, Perou CM, Stuart JM (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158(4):929–944. doi:10.1016/j.cell.2014.06.049 CrossRefPubMedPubMedCentral

Titel: FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma
verfasst von: Joshua I. Warrick
Matthew Kaag
Jay D. Raman
Wilson Chan
Truc Tran
Sudhir Kunchala
Lauren Shuman
David DeGraff
Guoli Chen
Publikationsdatum: 18.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 3/2017
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2190-3

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism

Erratum to: Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome

Prognostic impact of HER-2 Subclonal Amplification in breast cancer

Spectrum of lesions derived from branchial arches occurring in the thyroid: from solid cell nests to tumors

Intravascular large B cell lymphoma diagnosed in random duodenal biopsies. A case report and a literature review

Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien